You just read:

Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM)

News provided by

Viking Therapeutics, Inc.

Sep 07, 2017, 07:02 ET